Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869744 | 0.89 | USP2 (0.40) | USP2ALDH1A1CYP2C19MAPK1CYP2D6 | |
| SCHEMBL4861154 | 0.87 | CYP3A4 (0.46) | USP2ALDH1A1CYP2C19MAPK1CYP2D6 | |
| SCHEMBL4866342 | 0.86 | PDK2 (0.44) | ALDH1A1MAPK1TSHRPDK2OPRD1 | |
| SCHEMBL4863815 | 0.86 | L3MBTL1 (0.53) | ALDH1A1TSHRMEN1RAB9AKMT2A | |
| SCHEMBL4863798 | 0.84 | OPRL1 (0.44) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4871392 | 0.83 | OPRL1 (0.41) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4863081 | 0.82 | MEN1 (0.46) | CYP2C19MEN1RAB9AKMT2AOPRL1 | |
| SCHEMBL4867904 | 0.82 | OPRL1 (0.46) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4869997 | 0.80 | OPRL1 (0.40) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4864139 | 0.79 | OPRL1 (0.65) | ALDH1A1CYP2C19MAPK1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | claimed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | claimed |
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SULT1E1, TST, TMT1A | USP2 3612/4885ALDH1A1 359/4885CYP2C19 295/4885 |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | USP2 3858/4885ALDH1A1 2927/4885CYP2C19 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.